NICE
NICE recommends Bayer’s Stivarga for advanced hepatocellular carcinoma
November 29, 2018Sales and Marketing Bayer, NICE, Stivarga, UK, pharma
The National Institute for Health and Care Excellence (NICE) has voiced its recommendation for Bayer’s Stivarga (regorafenib) for use on …
Cancer Drugs Fund to offer MSD’s Keytruda for lung cancer
November 22, 2018Sales and Marketing CDF, Cancer, Cancer Drugs Fund, NHS, NICE, UK, keytruda, pharma
MSD’s Keytruda (pembrolizumab) will now be made available via the Cancer Drugs Fund for patients in England, as NICE announces …
Top Ten most popular articles on Pharmafile.com this week!
November 16, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Korea, NICE, Samsung, Theresa May, UK, brexit, politics, top 10
The Samsung scandal played a prominent role in this weeks’ top ten after the South Korean firm was delisted from …
Kymriah to be made available in UK for paediatric leukaemia patients via Cancer Drugs Fund
November 15, 2018Sales and Marketing CAR-T, Cancer, Cancer Drugs Fund, Kymriah, NHS, NICE, leukaemia, pharma
NICE has announced its recommendation that Novartis’ CAR-T cell therapy Kymriah (tisagenlecleucel) be made available in the treatment of relapsed …
Eisai’s Lenvima wins over NICE in liver cancer in just three months
November 9, 2018Medical Communications, Sales and Marketing Cancer, Eisai, Lenvima, Levantinib, NHS, NICE, UK, liver cancer, pharma
Eisai has revealed that its multireceptor Tyrosine Kinase Inhibitor Lenvima (lenvatinib) has been recommended by NICE, meaning it can now …
NICE fail to recommend AstraZeneca’s cancer drug Olaparib on cost effectiveness basis
November 9, 2018Medical Communications, Sales and Marketing AstraZeneca, NHS, NICE, UK, olaparib, pharma
Britain’s cost effectiveness body the National Institute of Health and Care Excellence (NICE) has chosen not to recommend AstraZeneca’s Olaparib …
Jazz Pharma’s Vyxeos secures NICE recommendation in acute myeloid leukaemia
November 8, 2018Sales and Marketing Cancer, NHS, NICE, UK, Vyxeos, acute myeloid leukaemia, jazz pharmaceuticals, pharma
Jazz Pharmaceuticals has revealed that NICE has chosen to recommend that its 44mg/100mg powder formulation of Vyxeos for concentrate for …
NICE appoints experienced pharma consultant as Director of NICE Scientific Advice
November 7, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing NICE, government, national institute of health and care excellence, politics, sciences
The National Institute for Health and Care Excellence (NICE) has appointed Jeanette Kusel as Director of NICE Scientific Advice. The …
Top Ten most popular articles on Pharmafile.com this week!
November 2, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AstraZeneca, GSK, ITH Pharma, J&J, JJ, NICE, Sanofi, Trump, top 10
Deals dominated the headlines this week as both Sanofi and AstraZeneca made billion dollar agreements. Meanwhile, the FDA gave magic …
NICE turns down Sanofi’s Caprelsa for rare thyroid cancer
October 31, 2018Research and Development, Sales and Marketing Cancer, Caprelsa, NHS, NICE, Sanofi, UK, medullary thyroid cancer, pharma
NICE has announced its recommendation to reject Sanofi’s Caprelsa (vandetanib) for use on the NHS in the treatment of medullary …
NICE issues draft guidance rejecting Abbvie’s Venclyxto in chronic lymphocytic leukaemia
October 26, 2018Medical Communications, Sales and Marketing AbbVie, NHS, NICE, leukaemia, pharma, venetoclax
It’s bad news for patients in the UK affected by chronic lymphocytic leukaemia (CLL) as the National Institute of Health …
NICE rejects Elil Lilly’s Verzenio for breast cancer in draft guidance
October 19, 2018Medical Communications, Sales and Marketing Eli Lilly, NICE, UK, Verzenios, breast cancer, pharma
Eli Lilly and patients with breast cancer patients in the UK have been dealt a blow as NICE confirmed that …
NICE recommends first new X-linked hypophosphataemia therapy in over 30 years
October 10, 2018Research and Development, Sales and Marketing Crysvita, Kyowa Kirin International, NHS, NICE, X-linked hypophosphataemia, pharma
NICE has announced its evidence-based recommendation that Kyowa Kirin International’s Crysvita (burosumab) be made available on the NHS for the …
NICE guidelines on antidepressant withdrawal symptoms are misleading, study shows
October 9, 2018Manufacturing and Production NICE, UK, addiction, antidepressants, research, study
Current NICE guidance concerning the severity of the effects of antidepressant withdrawal is misleading doctors according to research published in …
NICE recommends Pfizer’s Mylotarg combo in CD33-positive acute myeloid leukaemia
October 8, 2018Sales and Marketing Mylotarg, NICE, Pfizer, acute myeloid leukaemia, leukaemia, pharma
NICE has revealed its recommendation for Pfizer’s Mylotarg (gemtuzumab ozogamicin) to be used on the NHS in the treatment of …
Latest content
FibroFind appoints Lee Borthwick as CEO
